CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 5,727,789	$ 6,286,873	$ 17,203,823	$ 18,893,857
General and administrative	2,453,968	2,432,518	6,804,729	8,220,768
Total operating expenses	8,181,757	8,719,391	24,008,552	27,114,625
Operating loss	(8,181,757)	(8,719,391)	(24,008,552)	(27,114,625)
Gain on derivative instruments			0	366,791
Other non-operating losses			0	(30,793)
Interest expense, net	(181,670)	(913,193)	(493,522)	(1,460,055)
Other expense	(3,854)	0	(61,525)	0
Net loss	(8,367,281)	(9,632,584)	(24,563,599)	(28,238,682)
Modification of Warrants	0	(294,409)	(171,552)	(294,409)
Net loss available to common shareholders	$ (8,367,281)	$ (9,926,993)	$ (24,735,151)	$ (28,533,091)
Net loss per common share - basic and diluted	$ (0.19)	$ (0.23)	$ (0.57)	$ (0.66)
Weighted average common shares outstanding - basic and diluted	44,254,363	43,174,775	43,761,395	43,124,972